- Lumos Diagnostics (ASX:LDX) shares have shot up nearly 30 per cent today after inking two major agreements with US-based women’s health giant Hologic
- It includes a development and IP deal that’ll score Lumos around US$15 million
- Today’s news builds on a year-long partnership between the two companies
- LDX shares last traded at 10.5 cents
Lumos Diagnostics (ASX:LDX) surged nearly 30 per cent today after inking two major agreements with US-based women’s health giant Hologic.
A development deal will see Lumos earn up to US$4.7 million over the next 18-24 months, bolstering its finances and securing a valuable development pipeline in point-of-care diagnostics.
The other agreement grants Lumos a non-refundable US$10 million upfront payment for its intellectual property.
“This strategic partnership has highlighted the value of credible partners in supporting the translation of our unique, proprietary reader platform technology in frontline healthcare settings.”
This builds on a year-long partnership between the two companies, solidifying its commitment to delivering innovative solutions for women’s health.
LDX shares last traded at 10.5 cents.